America
New treatment offers hope for treating diabetes, MS
New York, March 5
Researchers have developed a novel and safe treatment for autoimmune diseases including Type-1 diabetes and multiple sclerosis (MS) that arise when the body's immune cells attack itself.
Current treatments eliminate these misfunctioning immune cells, but also destroy normal, protective immune cells, leaving patients susceptible to immune deficiency and opportunistic infections.
The new approach, by researchers from the University of Utah in the US, targets the misfunctioning immune cells while leaving the normal immune cells in place.
In the study, published in the journal Nature Biomedical Engineering, the team engineered a protein molecule to deplete the misfunctioning PD-1-expressing cells from the body while leaving normal immune cells in place.
"We wanted to target PD-1-expressing cells. Using this method, we may avoid long-term immune deficiency caused by common treatments for autoimmune disease," said lead author Peng Zhao, from the varsity.
When tested in a mouse model mimicking Type-1 diabetes, the treatment delayed the onset of diabetes.
"We are really taking treatment for the autoimmune disease in a new direction," said Mingnan Chen, Assistant Professor at the varsity.
"To make similar therapeutics for people, we would need to find the anti-human PD-1 antibody, like the anti-mouse PD-1 antibody.
"If we can generate the human version of therapeutics, I think we could make a huge impact in treating autoimmune disease," Chen said.
In addition, the treatment was also applied to a mouse MS model.
Besides halting the progression of paralysis, the treatment also restored the mice's ability to walk.
In a normal functioning immune system, the PD-1-expressing cells, including immune cells, contain a mechanism that prevents the cycle from attacking itself.
However, in people with autoimmune disease, these cells somehow escape the checkpoint and the immune system remains in a state of alert, attacking body cells.
Current treatments eliminate these misfunctioning immune cells, but also destroy normal, protective immune cells, leaving patients susceptible to immune deficiency and opportunistic infections.
The new approach, by researchers from the University of Utah in the US, targets the misfunctioning immune cells while leaving the normal immune cells in place.
In the study, published in the journal Nature Biomedical Engineering, the team engineered a protein molecule to deplete the misfunctioning PD-1-expressing cells from the body while leaving normal immune cells in place.
"We wanted to target PD-1-expressing cells. Using this method, we may avoid long-term immune deficiency caused by common treatments for autoimmune disease," said lead author Peng Zhao, from the varsity.
When tested in a mouse model mimicking Type-1 diabetes, the treatment delayed the onset of diabetes.
"We are really taking treatment for the autoimmune disease in a new direction," said Mingnan Chen, Assistant Professor at the varsity.
"To make similar therapeutics for people, we would need to find the anti-human PD-1 antibody, like the anti-mouse PD-1 antibody.
"If we can generate the human version of therapeutics, I think we could make a huge impact in treating autoimmune disease," Chen said.
In addition, the treatment was also applied to a mouse MS model.
Besides halting the progression of paralysis, the treatment also restored the mice's ability to walk.
In a normal functioning immune system, the PD-1-expressing cells, including immune cells, contain a mechanism that prevents the cycle from attacking itself.
However, in people with autoimmune disease, these cells somehow escape the checkpoint and the immune system remains in a state of alert, attacking body cells.
6 hours ago
Commuter Nightmare and Gridlock Causing Deadly Consequences in NY GW Bridge Ending in Murder!
7 hours ago
Illinois Lab Owner Charged in $66.2 Million COVID Testing Fraud Involving 380,000 Tests
7 hours ago
Diwali on Oak Tree Road to Illuminate New Jersey’s Indian Business District on October 25
10 hours ago
Trump says Google CEO Pichai dropped ‘American Ocean’ idea
10 hours ago
Oil tanker with 21 Indian seafarers struck by unknown projectile in Hormuz; all safe
10 hours ago
iPhone Duo could create 'Halo Effect' for Apple ecosystem: Industry experts
14 hours ago
Ningbo Open: Iva Jovic beats two-time Major finalist Paolini on debut
14 hours ago
Shilpa Shetty calls returning to Indian Idol after 22 years ‘a joy’, says Abhijeet Sawant’s smile is still the same
14 hours ago
Prajakta Koli says she wanted everyone who bought tickets for me to love me during ‘JugJugg Jeeyo’
14 hours ago
Uma Thurman recalls her first brush with the law at age three involving red high heels
14 hours ago
John Anderson passes away at 71, family says ‘we are completely heartbroken’
14 hours ago
Keerthy Suresh & Radhika Apte lead the rivalry tale between two powerful women in 'Akka'
14 hours ago
CMRL-Exalogic case: Vijayan moves Kerala HC to block further action of ED, Vigilance
